Shopping Cart 0
Cart Subtotal
AED 0

Biohaven Pharmaceutical Holding Company Ltd (BHVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Biohaven Pharmaceutical Holding Company Ltd (Biohaven), a subsidiary of Portage Biotech Inc, is a clinical-stage biopharmaceutical company that develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that includes two product candidates such as rimegepant (BHV-3000) for the acute treatment of migraine, and BHV-3500 for the prevention of a chronic and episodic migraine. Its glutamate modulation platform includes product candidates such as trigriluzole for the treatment of obsessive-compulsive disorder (OCD) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS); and BHV-5000 for treating symptoms associated with Rett syndrome and other neuropsychiatric indications. Biohaven is headquartered in New Haven, Connecticut, the US.

Biohaven Pharmaceutical Holding Company Ltd (BHVN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

Kleo Pharma Raises USD21 Million in Series B Financing 14

Biohaven Pharma Raises USD80 Million in Venture Financing 15

Kleo Pharma Raises Funds through Series A Financing 17

Partnerships 18

Biohaven Pharma and University of Connecticut Enter into Research Agreement 18

Biohaven Pharma Enters into Partnership with Alzheimer's Disease Cooperative Study 19

Licensing Agreements 20

Biohaven Pharma Enters into Licensing Agreement with University of Connecticut 20

Biohaven Therapeutics Enters into Licensing Agreement with AstraZeneca 21

Catalent UK Swindon Zydis Enters into Licensing Agreement with Biohaven Pharma 22

Biohaven Pharma Enters into Licensing Agreement with AstraZeneca 23

Biohaven Pharma Amends Licensing Agreement with Bristol-Myers Squibb 24

Biohaven Pharma Enters into Licensing Agreement with Rutgers, The State University of New Jersey 26

Biohaven Pharma Enters into Licensing Agreement with ALS Biopharma and Fox Chase Chemical Diversity Center 28

Biohaven Pharma Enters into Licensing Agreement with Catalent Pharma Solutions 29

Biohaven Pharma Enters into Licensing Agreement with General Hospital 30

Biohaven Pharma Enters into Licensing Agreement with Yale University 31

Equity Offering 32

Biohaven Pharma Plans to Raise up to USD4 Million in Public Offering of Shares 32

Biohaven Pharma Raises USD50 Million in Private Placement of Shares 33

Biohaven Pharma to Raise Funds through Public Offering of Shares 34

Biohaven Pharmaceutical Raises USD55 Million in Private Placement of Shares 35

Biohaven Pharma Raises USD193.5 Million in IPO 36

Biohaven Pharma Raises USD20 Million in Second Tranche of Private Placement of Shares 38

Biohaven Pharma Raises USD2.3 Million in Private Placement of Shares 40

Biohaven Pharma Raises USD4.1 Million in First Tranche of Private Placement of Shares 41

Asset Transactions 42

Royalty Pharma Acquires Approximately 2% Royalty Rights on Global Annual Net Sales of Rimegepant from Biohaven Pharma 42

Acquisition 43

Portage Biotech Acquires 54% Stake In Biohaven Pharma For USD3.5 Million 43

Biohaven Pharmaceutical Holding Company Ltd-Key Competitors 44

Biohaven Pharmaceutical Holding Company Ltd-Key Employees 45

Biohaven Pharmaceutical Holding Company Ltd-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Recent Developments 47

Financial Announcements 47

Aug 14, 2018: Biohaven Pharmaceuticals announces second quarter 2018 financial results 47

May 15, 2018: Biohaven Pharmaceuticals Announces First Quarter 2018 Financial Results 50

Mar 06, 2018: Biohaven Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results 52

Nov 14, 2017: Biohaven Pharmaceuticals Reports Third Quarter 2017 Financial And Business Results 54

Aug 14, 2017: Biohaven Pharmaceuticals Reports Second Quarter 2017 Financial And Business Results 56

Jun 19, 2017: Biohaven Pharmaceuticals Reports First Quarter 2017 Financial and Business Results 58

Corporate Communications 60

Sep 12, 2018: Biohaven Pharmaceutical appoints Bob Repella as board director 60

Nov 13, 2017: Biohaven Expands Finance Team With Appointment Of Senior Vice President 61

Oct 25, 2017: Biohaven Adds Clifford Bechtold as Chief Operating Officer 62

Aug 04, 2017: Biohaven Appoints Julia P. Gregory to Board of Directors 63

Jun 22, 2017: Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives 64

Mar 07, 2017: Biohaven Appoints Two New Directors To Board 65

Product News 66

12/21/2017: Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder 66

11/01/2017: Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with Amyotrophic Lateral Sclerosis 67

10/02/2017: Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia Phase 2/3 Trial 68

Sep 11, 2017: Biohaven To Provide Development Program Update At The Morgan Stanley 15th Annual Global Healthcare Conference 70

08/07/2017: Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017 71

08/03/2018: Biohaven enrols first patient in Phase ll/lll trial of trigriluzole 72

03/01/2018: Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis Orally Dissolving Tablet 73

01/09/2018: Biohaven announces Positive results from Bioequivalence study with sublingual BHV-0223 Zydis Orally Dissolving Tablet 74

Product Approvals 75

Jul 24, 2018: Biohaven initiates Phase 2/3 clinical trial of trigriluzole 75

May 09, 2018: Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS) 76

Oct 24, 2017: Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder 78

Jul 06, 2017: Biohavens BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome 79

May 15, 2017: Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA 80

Clinical Trials 81

Apr 22, 2018: Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine 81

Apr 19, 2018: Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles 82

Mar 26, 2018: Biohaven Announces Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine 83

Mar 06, 2018: Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis ODT In The Acute Treatment Of Migraine 84

Jan 18, 2018: Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist 85

Nov 27, 2017: Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant 86

Nov 20, 2017: Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine 87

Nov 16, 2017: Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine 88

Nov 06, 2017: Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223 89

Oct 30, 2017: Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute 90

Jul 31, 2017: Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine 91

Jul 24, 2017: Biohaven Enrolls First Patient in Pivotal Phase 3 Clinical Trial of Oral Rimegepant for the Acute Treatment of Migraine 92

May 30, 2017: Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole 93

Appendix 94

Methodology 94

About GlobalData 94

Contact Us 94

Disclaimer 94


List Of Figure

List of Figures

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10


List Of Table

List of Tables

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Biohaven Pharmaceutical Holding Company Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Kleo Pharma Raises USD21 Million in Series B Financing 14

Biohaven Pharma Raises USD80 Million in Venture Financing 15

Kleo Pharma Raises Funds through Series A Financing 17

Biohaven Pharma and University of Connecticut Enter into Research Agreement 18

Biohaven Pharma Enters into Partnership with Alzheimer's Disease Cooperative Study 19

Biohaven Pharma Enters into Licensing Agreement with University of Connecticut 20

Biohaven Therapeutics Enters into Licensing Agreement with AstraZeneca 21

Catalent UK Swindon Zydis Enters into Licensing Agreement with Biohaven Pharma 22

Biohaven Pharma Enters into Licensing Agreement with AstraZeneca 23

Biohaven Pharma Amends Licensing Agreement with Bristol-Myers Squibb 24

Biohaven Pharma Enters into Licensing Agreement with Rutgers, The State University of New Jersey 26

Biohaven Pharma Enters into Licensing Agreement with ALS Biopharma and Fox Chase Chemical Diversity Center 28

Biohaven Pharma Enters into Licensing Agreement with Catalent Pharma Solutions 29

Biohaven Pharma Enters into Licensing Agreement with General Hospital 30

Biohaven Pharma Enters into Licensing Agreement with Yale University 31

Biohaven Pharma Plans to Raise up to USD4 Million in Public Offering of Shares 32

Biohaven Pharma Raises USD50 Million in Private Placement of Shares 33

Biohaven Pharma to Raise Funds through Public Offering of Shares 34

Biohaven Pharmaceutical Raises USD55 Million in Private Placement of Shares 35

Biohaven Pharma Raises USD193.5 Million in IPO 36

Biohaven Pharma Raises USD20 Million in Second Tranche of Private Placement of Shares 38

Biohaven Pharma Raises USD2.3 Million in Private Placement of Shares 40

Biohaven Pharma Raises USD4.1 Million in First Tranche of Private Placement of Shares 41

Royalty Pharma Acquires Approximately 2% Royalty Rights on Global Annual Net Sales of Rimegepant from Biohaven Pharma 42

Portage Biotech Acquires 54% Stake In Biohaven Pharma For USD3.5 Million 43

Biohaven Pharmaceutical Holding Company Ltd, Key Competitors 44

Biohaven Pharmaceutical Holding Company Ltd, Key Employees 45

Biohaven Pharmaceutical Holding Company Ltd, Subsidiaries 46

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Biohaven Pharmaceutical Holding Company Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Biohaven Pharmaceutical Holding Company Ltd (Biohaven), a subsidiary of Portage Biotech Inc, is a clinical-stage biopharmaceutical company that develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that includes two product candidates such as rimegepant (BHV-3000) for the acute treatment of migraine, and BHV-3500 for the prevention of a chronic and episodic migraine. Its glutamate modulation platform includes product candidates such as trigriluzole for the treatment of obsessive-compulsive disorder (OCD) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS); and BHV-5000 for treating symptoms associated with Rett syndrome and other neuropsychiatric indications. Biohaven is headquartered in New Haven, Connecticut, the US.

Biohaven Pharmaceutical Holding Company Ltd (BHVN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

Kleo Pharma Raises USD21 Million in Series B Financing 14

Biohaven Pharma Raises USD80 Million in Venture Financing 15

Kleo Pharma Raises Funds through Series A Financing 17

Partnerships 18

Biohaven Pharma and University of Connecticut Enter into Research Agreement 18

Biohaven Pharma Enters into Partnership with Alzheimer's Disease Cooperative Study 19

Licensing Agreements 20

Biohaven Pharma Enters into Licensing Agreement with University of Connecticut 20

Biohaven Therapeutics Enters into Licensing Agreement with AstraZeneca 21

Catalent UK Swindon Zydis Enters into Licensing Agreement with Biohaven Pharma 22

Biohaven Pharma Enters into Licensing Agreement with AstraZeneca 23

Biohaven Pharma Amends Licensing Agreement with Bristol-Myers Squibb 24

Biohaven Pharma Enters into Licensing Agreement with Rutgers, The State University of New Jersey 26

Biohaven Pharma Enters into Licensing Agreement with ALS Biopharma and Fox Chase Chemical Diversity Center 28

Biohaven Pharma Enters into Licensing Agreement with Catalent Pharma Solutions 29

Biohaven Pharma Enters into Licensing Agreement with General Hospital 30

Biohaven Pharma Enters into Licensing Agreement with Yale University 31

Equity Offering 32

Biohaven Pharma Plans to Raise up to USD4 Million in Public Offering of Shares 32

Biohaven Pharma Raises USD50 Million in Private Placement of Shares 33

Biohaven Pharma to Raise Funds through Public Offering of Shares 34

Biohaven Pharmaceutical Raises USD55 Million in Private Placement of Shares 35

Biohaven Pharma Raises USD193.5 Million in IPO 36

Biohaven Pharma Raises USD20 Million in Second Tranche of Private Placement of Shares 38

Biohaven Pharma Raises USD2.3 Million in Private Placement of Shares 40

Biohaven Pharma Raises USD4.1 Million in First Tranche of Private Placement of Shares 41

Asset Transactions 42

Royalty Pharma Acquires Approximately 2% Royalty Rights on Global Annual Net Sales of Rimegepant from Biohaven Pharma 42

Acquisition 43

Portage Biotech Acquires 54% Stake In Biohaven Pharma For USD3.5 Million 43

Biohaven Pharmaceutical Holding Company Ltd-Key Competitors 44

Biohaven Pharmaceutical Holding Company Ltd-Key Employees 45

Biohaven Pharmaceutical Holding Company Ltd-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Recent Developments 47

Financial Announcements 47

Aug 14, 2018: Biohaven Pharmaceuticals announces second quarter 2018 financial results 47

May 15, 2018: Biohaven Pharmaceuticals Announces First Quarter 2018 Financial Results 50

Mar 06, 2018: Biohaven Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results 52

Nov 14, 2017: Biohaven Pharmaceuticals Reports Third Quarter 2017 Financial And Business Results 54

Aug 14, 2017: Biohaven Pharmaceuticals Reports Second Quarter 2017 Financial And Business Results 56

Jun 19, 2017: Biohaven Pharmaceuticals Reports First Quarter 2017 Financial and Business Results 58

Corporate Communications 60

Sep 12, 2018: Biohaven Pharmaceutical appoints Bob Repella as board director 60

Nov 13, 2017: Biohaven Expands Finance Team With Appointment Of Senior Vice President 61

Oct 25, 2017: Biohaven Adds Clifford Bechtold as Chief Operating Officer 62

Aug 04, 2017: Biohaven Appoints Julia P. Gregory to Board of Directors 63

Jun 22, 2017: Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives 64

Mar 07, 2017: Biohaven Appoints Two New Directors To Board 65

Product News 66

12/21/2017: Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder 66

11/01/2017: Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with Amyotrophic Lateral Sclerosis 67

10/02/2017: Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia Phase 2/3 Trial 68

Sep 11, 2017: Biohaven To Provide Development Program Update At The Morgan Stanley 15th Annual Global Healthcare Conference 70

08/07/2017: Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017 71

08/03/2018: Biohaven enrols first patient in Phase ll/lll trial of trigriluzole 72

03/01/2018: Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis Orally Dissolving Tablet 73

01/09/2018: Biohaven announces Positive results from Bioequivalence study with sublingual BHV-0223 Zydis Orally Dissolving Tablet 74

Product Approvals 75

Jul 24, 2018: Biohaven initiates Phase 2/3 clinical trial of trigriluzole 75

May 09, 2018: Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS) 76

Oct 24, 2017: Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder 78

Jul 06, 2017: Biohavens BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome 79

May 15, 2017: Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA 80

Clinical Trials 81

Apr 22, 2018: Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine 81

Apr 19, 2018: Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles 82

Mar 26, 2018: Biohaven Announces Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine 83

Mar 06, 2018: Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis ODT In The Acute Treatment Of Migraine 84

Jan 18, 2018: Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist 85

Nov 27, 2017: Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant 86

Nov 20, 2017: Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine 87

Nov 16, 2017: Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine 88

Nov 06, 2017: Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223 89

Oct 30, 2017: Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute 90

Jul 31, 2017: Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine 91

Jul 24, 2017: Biohaven Enrolls First Patient in Pivotal Phase 3 Clinical Trial of Oral Rimegepant for the Acute Treatment of Migraine 92

May 30, 2017: Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole 93

Appendix 94

Methodology 94

About GlobalData 94

Contact Us 94

Disclaimer 94


List Of Figure

List of Figures

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10


List Of Table

List of Tables

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Biohaven Pharmaceutical Holding Company Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Kleo Pharma Raises USD21 Million in Series B Financing 14

Biohaven Pharma Raises USD80 Million in Venture Financing 15

Kleo Pharma Raises Funds through Series A Financing 17

Biohaven Pharma and University of Connecticut Enter into Research Agreement 18

Biohaven Pharma Enters into Partnership with Alzheimer's Disease Cooperative Study 19

Biohaven Pharma Enters into Licensing Agreement with University of Connecticut 20

Biohaven Therapeutics Enters into Licensing Agreement with AstraZeneca 21

Catalent UK Swindon Zydis Enters into Licensing Agreement with Biohaven Pharma 22

Biohaven Pharma Enters into Licensing Agreement with AstraZeneca 23

Biohaven Pharma Amends Licensing Agreement with Bristol-Myers Squibb 24

Biohaven Pharma Enters into Licensing Agreement with Rutgers, The State University of New Jersey 26

Biohaven Pharma Enters into Licensing Agreement with ALS Biopharma and Fox Chase Chemical Diversity Center 28

Biohaven Pharma Enters into Licensing Agreement with Catalent Pharma Solutions 29

Biohaven Pharma Enters into Licensing Agreement with General Hospital 30

Biohaven Pharma Enters into Licensing Agreement with Yale University 31

Biohaven Pharma Plans to Raise up to USD4 Million in Public Offering of Shares 32

Biohaven Pharma Raises USD50 Million in Private Placement of Shares 33

Biohaven Pharma to Raise Funds through Public Offering of Shares 34

Biohaven Pharmaceutical Raises USD55 Million in Private Placement of Shares 35

Biohaven Pharma Raises USD193.5 Million in IPO 36

Biohaven Pharma Raises USD20 Million in Second Tranche of Private Placement of Shares 38

Biohaven Pharma Raises USD2.3 Million in Private Placement of Shares 40

Biohaven Pharma Raises USD4.1 Million in First Tranche of Private Placement of Shares 41

Royalty Pharma Acquires Approximately 2% Royalty Rights on Global Annual Net Sales of Rimegepant from Biohaven Pharma 42

Portage Biotech Acquires 54% Stake In Biohaven Pharma For USD3.5 Million 43

Biohaven Pharmaceutical Holding Company Ltd, Key Competitors 44

Biohaven Pharmaceutical Holding Company Ltd, Key Employees 45

Biohaven Pharmaceutical Holding Company Ltd, Subsidiaries 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Biohaven Pharmaceutical Holding Company Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.